Highlights of This Issue 6059

SPECIAL FEATURES

CCR Translations

6061  Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed
Dung T. Le and Elizabeth M. Jaffee
See related article, p. 6286

6064  Test-Firing Ammunition for Spliceosome Inhibition in Cancer
Scott M. Dehm
See related article, p. 6296

CCR Perspectives in Drug Approval

6067  Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary

Molecular Pathways

6074  Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer
Louise R. Howe, Kotha Subbaramaiah, Clifford A. Hudis, and Andrew J. Dannenberg

6084  Molecular Pathways: Induction of Polyploidy as a Novel Differentiation Therapy for Leukemia
Diane S. Krause and John D. Crispino

Review

6089  Lessons Learned from Radiation Oncology Clinical Trials
Fei-Fei Liu, for the workshop participants, Paul Okunieff, Eric J. Bernhard, Helen B. Stone, Stephen Yoo, C. Norman Coleman, Bhadrasain Vikram, Martin Brown, John Buatti, and Chandan Guha

HUMAN CANCER BIOLOGY

6101  Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer
Yi Ding, Dandan He, Diego Florentin, Anna Frolov, Sue Hilsenbeck, Michael Ittmann, Dov Kadmian, Brian Miles, David Rowley, and Gustavo Ayala

6112  Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

6126  Hypoxic Activation of the PERK/eIF2α Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3
Hilda Mujic, Anika Nagelkerke, Kasper M.A. Rouschop, Naz Chaudary, Paul N. Span, Blaise Clarke, Michael Milosevic, Jenna Sykes, Richard P. Hill, Marianne Koritzinsky, and Bradly G. Wouters

CANCER THERAPY: PRECLINICAL

6138  Adrenomedullin Blockade Suppresses Growth of Human Hormone–Independent Prostate Tumor Xenograft in Mice
CANCER THERAPY: CLINICAL

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
See related article, p. 6061

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Francisco J. Ramos, Herman Burger, James P. O’Brien, Adelaida Piera, Maja J.A. de Jonge, Yoshiharu Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, José Baselga, and Josep Tabernero
See related article, p. 6064

Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

LETTERS TO THE EDITOR

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response
Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steufl, Lisa Zimmer, and Dirk Schadendorf

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Cellular internalization of siRNA (red fluorescence) delivered by the nanocarrier (green fluorescence) specifically targeted to cancer cells. Superimposition of red (siRNA) and green (nanocarrier) fluorescence images gives yellow color. For details, see the article by Shah and colleagues on page 6193 of this issue.
Clinical Cancer Research

19 (22)


| Updated version | Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/19/22 |

| E-mail alerts      | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions       | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |